Objective: The oral minimal model (OMM) is a powerful tool to assess beta-cell function, including both the dynamic and static states. Dorzagliatin, a novel dual-acting glucokinase activator, has been reported the potential to improve pancreatic function in patients with type-2 diabetes mellitus (T2DM). In this study, we aimed to evaluate the effects of dorzagliatin on beta-cell function by using OMM.

Methods: A randomized, double-blind, placebo-controlled study of dorzagliatin following multiple ascending doses in T2DM was completed (NCT02077452) and the data collected were used for beta-cell function parameters (Φb, Φd, Φs, and Φtot) estimation by using the SAAM II package integrating OMM. These parameters represent the non-glucose stimulated index, the dynamic responsivity of insulin secretion, the static responsivity of insulin secretion, and the global index of beta-cell responsivity, respectively.

Results: All treatments except for the 200 mg dose group, compared with baseline, were associated with higher beta-cell function indices. Among them, Φb was significantly higher in the 25, 50, 100, and 150 mg dose groups (p < 0.05, p < 0.01, or p < 0.001), indicating basal beta-cell responsivity improved. Φd has an increase in the 25 and 100 mg dose groups (p < 0.05), indicating promptly releasable insulin responsivity improved. Φs was higher in the 25, 50, 100, and 150 mg dose groups (p < 0.05 or p < 0.01), indicating insulin secretion responsivity at steady state improved. Φtot significantly increased in the 25, 50, 100, and 150 mg dose groups (p < 0.05 or p < 0.001), indicating total beta-cell responsivity improved. No statistically significant difference was observed within the placebo group.

Conclusions: This study suggested dorzagliatin can improve postprandial glucose control through its positive effects on beta-cell function.


Y. Zhang: None. L. Feng: Employee; Hua Medicine. L. Chen: Employee; Hua Medicine. D. Liu: None.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.